IGH/MYEOV Plus Translocation, Dual Fusion
The most common translocation in Multiple Myeloma (MM) is the t(11;14)(q13;q32)1, which accounts for 15-20% of cases as identified by FISH2.
Unlike Mantle Cell Lymphoma (MCL), where the breakpoints are clustered in a 1kb region that is 120kb centromeric to the CCND1 gene3, the breakpoints in Multiple Myeloma cases are dispersed within a 360kb region between CCND1 and MYEOV (MYEloma OVerexpressed) in band 11q134. MYEOV is a putative oncogene, located 360kb away from CCND1, which is thought to be activated in the translocation by becoming closely associated with IGH enhancers. In contrast to IGH rearrangements in other neoplasms, those found in Multiple Myeloma have IGH breakpoints predominantly in the C/J region, which, in the case of MYEOV, brings the MYEOV gene under the control of the 3' Eα1 enhancer4. In CCND1 translocations by contrast, the Eμ enhancer controls CCND1 expression. MYEOV overexpression is a possible prognostic factor in MM5.
1. Fonseca et al., Br J Haematol 1998;101(2):296-301
2. Bergsagel et al., Oncogene 2001;20(40):5611-5622
3. Ronchetti et al., Blood 1999 93(4):1330-1337
4. Janssen et al., Blood. 2000 15;95(8):2691-8
5. Moreaux et al., Exp Haematol 2010;38(12):1189-1198
- Area of Interest*
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.